Takeda called on to take corrective action over Alinamin-F5 marketing and manufacturing

15 February 2013

Japan’s largest drugmaker Takeda Pharmaceutical (TYO: 4502) revealed it has received an Order for Corrective Action regarding the manufacturing and marketing of AlinaminL-F5 Injection, a vitamin E-fortified B1, B2 and B12 product, from the Osaka Prefectural government, citing a violation of the Pharmaceutical Affairs Act associated with the voluntary recall of Lot H123 of the product.

Also, the manufacturing site of this product, the Osaka plant (located in Izumisano City) of Nihon Pharmaceutical, a contract manufacturer and subsidiary of Takeda, received the order for temporary suspension of its operations from the Osaka Prefectural Government for the period of 12 days from February 14 to February 25.

Background to this issue

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK